Transdifferentiation of Adult Cell Types to ?-cells: Therapeutic Potential for Type 1 Diabetes
2012
- 4Usage
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Usage4
- Abstract Views4
Article Description
Given the prevalence of type I diabetes and the insufficient treatments currently available, research concerning new therapies is crucial. The most promising and exciting therapy is transdifferentiation. That is, the heritable change of one cell identity into another. Three modes of transdifferentiation are discussed to regenerate beta-cells, including liver cells to beta-cells, pancreatic exocrine cells to beta-cells and alpha-cells to beta-cells. While further research is required before transdifferentiation can evolve safely, the pre-clinical research discussed here is a vital first step in pursuing this promising therapy for diabetes.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know